Literature DB >> 19954245

Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

Juan Pablo Cueva1, Tingwei Bill Cai, S Wayne Mascarella, James B Thomas, Hernán A Navarro, F Ivy Carroll.   

Abstract

In previous structure-activity relationship (SAR) studies, (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 3) was identified as the first potent and selective kappa-opioid receptor antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonists. In the present study, we report the synthesis of analogues 8a-p of 3 and present their in vitro opioid receptor functional antagonism using a [(35)S]GTPgammaS binding assay. Compounds 8a-p are analogues of 3 containing one, two, or three methyl groups connected to the JDTic structure at five different positions. All the analogues with one and two added methyl groups with the exception of 8k had subnanomolar K(e) values at the kappa receptor. The three most potent analogues were the monomethylated (3R)-7-hydroxy-N-[(1S,2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidine-1-yl]methyl}-2-methylbutyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (8a) and (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-(2-methylpropyl)]-3-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (8e) with K(e) values of 0.03 nM at the kappa receptor and (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-methoxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (8d) with K(e) = 0.037 nM at the kappa receptor. All three compounds were selective for the kappa receptor relative to the micro and delta receptors. Overall, the results from this study highlight those areas that are tolerant to substitution on 3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19954245      PMCID: PMC5584631          DOI: 10.1021/jm900756t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration.

Authors:  D E Clark
Journal:  J Pharm Sci       Date:  1999-08       Impact factor: 3.534

Review 2.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

Review 3.  The mesolimbic dopamine reward circuit in depression.

Authors:  Eric J Nestler; William A Carlezon
Journal:  Biol Psychiatry       Date:  2006-03-29       Impact factor: 13.382

4.  N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

Authors:  F Ivy Carroll; Sachin Chaudhari; James B Thomas; S Wayne Mascarella; Kenneth M Gigstad; Jeffrey Deschamps; Hernán A Navarro
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

5.  Synthesis and biological evaluation of two analogues of (S)-alpha-methyl-3-carboxyphenylalanine.

Authors:  D Ma; Z Ma; A P Kozikowski; S Pshenichkin; J T Wroblewski
Journal:  Bioorg Med Chem Lett       Date:  1998-09-22       Impact factor: 2.823

6.  General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions.

Authors:  R J Bodnar; M J Glass; A Ragnauth; M L Cooper
Journal:  Brain Res       Date:  1995-11-27       Impact factor: 3.252

7.  Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.

Authors:  William A Carlezon; Cécile Béguin; Jennifer A DiNieri; Michael H Baumann; Michele R Richards; Mark S Todtenkopf; Richard B Rothman; Zhongze Ma; David Y-W Lee; Bruce M Cohen
Journal:  J Pharmacol Exp Ther       Date:  2005-10-13       Impact factor: 4.030

8.  Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.

Authors:  Allison T Knoll; Edward G Meloni; James B Thomas; F Ivy Carroll; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2007-09-06       Impact factor: 4.030

9.  Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Authors:  Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

10.  The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.

Authors:  Benjamin B Land; Michael R Bruchas; Julia C Lemos; Mei Xu; Erica J Melief; Charles Chavkin
Journal:  J Neurosci       Date:  2008-01-09       Impact factor: 6.167

View more
  10 in total

1.  Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats.

Authors:  Patrick M Beardsley; Gerald T Pollard; James L Howard; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

2.  N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands.

Authors:  Kevin J Frankowski; Partha Ghosh; Vincent Setola; Thuy B Tran; Bryan L Roth; Jeffrey Aubé
Journal:  ACS Med Chem Lett       Date:  2010-08-12       Impact factor: 4.345

3.  Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.

Authors:  Erica J Melief; Mayumi Miyatake; F Ivy Carroll; Cécile Béguin; William A Carlezon; Bruce M Cohen; Sarah Grimwood; Charles H Mitch; Linda Rorick-Kehn; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2011-08-10       Impact factor: 4.436

4.  Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[11C]methoxyphenethyl)pyridazin-3(2H)-one, a 11C-labeled d-amino acid oxidase (DAAO) inhibitor for PET imaging.

Authors:  Xiaoyun Deng; Yiding Zhang; Zhen Chen; Katsushi Kumata; Richard Van; Jian Rong; Tuo Shao; Akiko Hatori; Wakana Mori; Qingzhen Yu; Kuan Hu; Masayuki Fujinaga; Hsiao-Ying Wey; Yihan Shao; Lee Josephson; Giulia Murtas; Loredano Pollegioni; Ming-Rong Zhang; Steven Liang
Journal:  Bioorg Med Chem Lett       Date:  2020-06-09       Impact factor: 2.823

Review 5.  The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.

Authors:  F Ivy Carroll; Roland E Dolle
Journal:  ChemMedChem       Date:  2014-06-30       Impact factor: 3.466

6.  Characterization of BU09059: a novel potent selective κ-receptor antagonist.

Authors:  Joseph J Casal-Dominguez; Daniel Furkert; Mehrnoosh Ostovar; Linnea Teintang; Mary J Clark; John R Traynor; Stephen M Husbands; Sarah J Bailey
Journal:  ACS Chem Neurosci       Date:  2014-01-28       Impact factor: 4.418

7.  Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.

Authors:  S Michael Owens; Gerald T Pollard; James L Howard; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  ACS Chem Neurosci       Date:  2016-10-04       Impact factor: 4.418

8.  Enantioselective Synthesis of Tetrahydroquinolines, Tetrahydroquinoxalines, and Tetrahydroisoquinolines via Pd-Catalyzed Alkene Carboamination Reactions.

Authors:  B A Hopkins; J P Wolfe
Journal:  Chem Sci       Date:  2014-12-01       Impact factor: 9.825

9.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

Authors:  Chad M Kormos; Pauline W Ondachi; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

Review 10.  Development of κ opioid receptor antagonists.

Authors:  F Ivy Carroll; William A Carlezon
Journal:  J Med Chem       Date:  2013-02-14       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.